Selected as a Startup in the Second Cohort of “Kido NEXT”

FerroptoCure Co., Ltd. (Representative Director: Yuji Otsuki) is pleased to announce that it has been selected as one of the startups accepted into the second cohort of “Kido NEXT,” a program designed to support the business growth and societal implementation of deep-tech startups.

“Kido NEXT” is a support program that promotes collaboration between deep-tech startups possessing cutting-edge technologies and corporations and research institutions, with the goal of facilitating the societal implementation of innovative technologies. For the second cohort, startups with high growth potential were selected from fields such as life sciences, environment and energy, and AI and robotics.

Taking this selection for “Kido NEXT” as an opportunity, we will further strengthen our collaborations with commercial companies and research institutions to accelerate our research and development as well as commercialization efforts. As a leading company in Ferrotosis-based drug discovery, we will continue to deliver new treatment opportunities to patients with intractable cancers and strive to realize a “world free from the suffering of cancer.”

関連記事：第2期 採択スタートアップ - 起動 NEXT
関連ページ　Sciencehttps://ferroptocure.com/en/science-pipeline/science/